Patents by Inventor Ikbel Achour

Ikbel Achour has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240075160
    Abstract: Provided herein are methods of treating cancer in a human subject, comprising administering to the subject: i) an antibody-drug conjugate (ADC) comprising an antibody, a cleavable linker and a cytotoxic agent, and ii) a bispecific checkpoint inhibitor. Further provided herein are kits comprising i) an antibody-drug conjugate (ADC) comprising an antibody, a cleavable linker and a cytotoxic agent, and ii) a bispecific checkpoint inhibitor.
    Type: Application
    Filed: July 27, 2023
    Publication date: March 7, 2024
    Inventors: Bilal OMAR, Scott A. HAMMOND, Judith ANDERTON, Nadia LUHESHI, Daniel J. FREEMAN, Krista KINNEER, Jorge ZERON-MEDINA CUAIRAN, Ikbel ACHOUR, Doug PALMER
  • Publication number: 20230420081
    Abstract: Methods for determining treatments for cancer patients are disclosed.
    Type: Application
    Filed: September 13, 2023
    Publication date: December 28, 2023
    Inventors: Li Yu, Harry Yang, Mohammed Dar, Lorin Roskos, Jean-Charles Soria, Charles Ferte, Wei Zhao, Aline Gendrin Brokmann, Jolyon Faria, Pralay Mukhopadhyay, Ikbel Achour
  • Patent number: 11798653
    Abstract: Methods for determining treatments for cancer patients are disclosed.
    Type: Grant
    Filed: October 18, 2019
    Date of Patent: October 24, 2023
    Assignee: MEDIMMUNE, LLC
    Inventors: Li Yu, Harry Yang, Mohammed Dar, Lorin Roskos, Jean-Charles Soria, Charles Ferte, Wei Zhao, Aline Gendrin Brokmann, Jolyon Faria, Pralay Mukhopadhyay, Ikbel Achour
  • Publication number: 20230322928
    Abstract: The present disclosure provides methods of administering bispecific antibodies and antigen-binding fragments thereof that specifically bind to human Programmed cell-death-1 (PD-1) and Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) to a subject in need thereof, for example, a subject with cancer.
    Type: Application
    Filed: March 6, 2023
    Publication date: October 12, 2023
    Inventors: Daniel J. FREEMAN, Xuyang SONG, Shelby GAINER, Deepa SUBRAMANIAM, Ikbel ACHOUR, Charles FERTE
  • Publication number: 20200051661
    Abstract: Functionally altered biological mechanisms arising from disease-associated polymorphisms remain difficult to characterize when those variants are intergenic, or, fall between genes. The present invention uses computational modelling of single-nucleotide polymorphisms (SNPs) drawn from genome-wide association studies (GWAS) or other databases to identify SNP pairs, including SNP pairs where at least one SNP is outside a protein-coding region of a gene, having convergent biological mechanisms. Additional databases, including genomic databases, biological regulatory databases, and databases related to molecular function, are used to further identify and validate the similarity of the biological mechanisms of the SNP pairs. Prioritized SNP pairs having increased similarity of biological mechanisms are then used to identify disease mechanisms, candidate therapeutic drugs, and candidate therapeutic targets among downstream effectors of intergenic SNPs.
    Type: Application
    Filed: October 12, 2017
    Publication date: February 13, 2020
    Applicant: Arizona Board of Regents on Behalf of the University of Arizona
    Inventors: Haiquan LI, Ikbel ACHOUR, Joanne BERGHOUT, Yves A. LUSSIER
  • Patent number: 10040870
    Abstract: Disclosed is an immune library obtained from a Camelid species containing at antibody chains belonging to at least 7 human germline antibody chains. The presence of a large number of human germline antibody chain families in the library contributes to the usefulness of the library in producing antibodies to human target antigens. The antibodies produced from the library have low inherent immunogenicity.
    Type: Grant
    Filed: September 2, 2013
    Date of Patent: August 7, 2018
    Assignee: argenx BVBA
    Inventors: Johannes Joseph Wilhelmus De Haard, Christophe Frederic Jerome Blanchetot, Alex Klarenbeek, Ikbel Achour, Khalil El Mazouari, Jurgen Del Favero
  • Publication number: 20160239620
    Abstract: A system and method of predicting the course of progression of a disease and determining a personalized therapeutic regime for treating the disease in a subject includes obtaining the subject's normal-tissue transcriptome. The normal-tissue transcriptome is statistically correlated with the subject's perturbed transcriptome to identify one or more deregulated mechanisms; and statistics derived from the identified deregulated mechanism are used to predict the course of progression of the disease and to a recommend a personalized therapeutic regime for treating the disease. The perturbed transcriptome may in some cases be determined from a cancer of the subject, and in other cases from viral infected tissue cultured from the subject.
    Type: Application
    Filed: October 2, 2014
    Publication date: August 18, 2016
    Inventors: Yves André LUSSIER, Vincent GARDEUX, Ikbel ACHOUR
  • Publication number: 20150166680
    Abstract: Disclosed is an immune library obtained from a Camelid species containing at antibody chains belonging to at least 7 human germline antibody chains. The presence of a large number of human germline antibody chain families in the library contributes to the usefulness of the library in producing antibodies to human target antigens. The antibodies produced from the library have low inherent immunogenicity.
    Type: Application
    Filed: September 2, 2013
    Publication date: June 18, 2015
    Inventors: Johannes Joseph Wilhelmus De Haard, Christophe Frederic Jerome Blanchetot, Alex Klarenbeek, Ikbel Achour, Khalil El Mazouari, Jurgen Del Favero